Multiple Sclerosis News Today

Stopping Ocrevus in stable MS doesn’t seem to raise 2-year risk, study finds

In stable MS patients, stopping Ocrevus does not seem to increase the risk of disease activity or disability progression for ...
Seeking Alpha

Genentech Presents New Data for Ocrevus and Fenebrutinib Across Broad Patient Populations at ECTRIMS 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presents new data for Ocrevus ® (ocrelizumab) and the investigational Bruton’s ...
Seeking Alpha

Genentech Provides Update on Phase III Ocrevus High Dose Study in People With Relapsing Multiple Sclerosis

- MUSETTE trial was designed to determine whether a higher dose of the currently approved Ocrevus IV 600 mg would provide additional benefit to people living with relapsing multiple sclerosis - - The ...
Healthline

Briumvi vs. Ocrevus: What You Should Know

Briumvi (ublituximab-xiiy) and Ocrevus (ocrelizumab) are prescription drugs used to treat certain types of multiple sclerosis (MS). Both drugs are given as an intravenous (IV) infusion by a healthcare ...
Nasdaq

FDA Approves Ocrevus Zunovo™ as the First and Only Twice-a-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis

– Ocrevus Zunovo™ has the potential to expand treatment options to centers without IV infrastructure or with IV constraints, like at a doctor's office – – This approval is backed by a decade of proven ...